Pandey et al. (2015) showed that higher antibody levels specific to wild-type EGFR or EGFRvIII, which were associated with immunoglobulin allotypes, were related to improved overall survival in GBM patients. Olsen et al. (2013) reported a negative correlation between autoantibody levels against EGFR in serum and disease free survival in breast cancer patients with relapse or death. This evidence concerns the gene EGFR and breast cancer.